Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04714372
Title FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota

acute myeloid leukemia


Cyclophosphamide + Fludarabine

Daratumumab and hyaluronidase-fihj + FT538

Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.